Non-exudative Age-related Macular Degeneration
8
0
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (8)
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
Transpalpebral Microcurrent Stimulation for the Improvement of Visual Acuity in Patients With Macular Degeneration
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Directional Spread in Geographic Atrophy
Non-exudative Age-related Macular Degeneration
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration